Your browser doesn't support javascript.
Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds.
Bilyy, Rostyslav; Pagneux, Quentin; François, Nathan; Bila, Galyna; Grytsko, Roman; Lebedin, Yuri; Barras, Alexandre; Dubuisson, Jean; Belouzard, Sandrine; Séron, Karin; Boukherroub, Rabah; Szunerits, Sabine.
  • Bilyy R; Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine.
  • Pagneux Q; University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France.
  • François N; U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France.
  • Bila G; Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine.
  • Grytsko R; Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine.
  • Lebedin Y; Xema Co. Ltd., Akademika Efremova Str., 23, 03179 Kyiv, Ukraine.
  • Barras A; University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France.
  • Dubuisson J; U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France.
  • Belouzard S; U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France.
  • Séron K; U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France.
  • Boukherroub R; University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France.
  • Szunerits S; University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France.
Pathogens ; 10(7)2021 Jul 08.
Article in English | MEDLINE | ID: covidwho-1302436
ABSTRACT
Vaccination remains one of the most effective tools to prevent infectious diseases. To ensure that the best possible antigenic components are chosen to stimulate a cognitive immune response, boosting antigen presentation using adjuvants is common practice. Nanodiamond-based adjuvants are proposed here as a rapid and versatile platform for antigen conjugation, utilizing peptides common to different pathogenic strains and making this strategy a good candidate for a "ready-to-use" vaccine. Initiation of an inflammatory reaction with a resulting immune response is based on the ability of living organisms to entrap nanostructures such as nanodiamonds with neutrophil extracellular traps (NETs) formation. In this work, coronavirus peptide homological for MERS-CoV, fusion inhibitor, was conjugated to nanodiamonds and used to induce neutrophilic-driven self-limiting inflammation. The resulting adjuvant was safe and did not induce any tissue damage at the site of injection. Mice immunization resulted in IgG titers of »,000 within 28 days. Immunization of rabbits resulted in the formation of a high level of antibodies persistently present for up to 120 days after the first immunization (animal lifespan ~3 years). The peptide used for immunization proved to be reactive with sera of convalescent COVID patients, demonstrating the possibility of developing pancoronaviral vaccine candidates.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Pathogens10070861

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Pathogens10070861